Story perspectives

Kalshi launches biotech bets; Merck gets PCSK9, EBV-MS link.

7/16/2026

Summary

Story summary

Kalshi announced it will launch biopharma betting markets that let users wager on trial results and FDA approvals, beginning with markets selected with AppliedXL, a firm that predicts trial outcomes, and aims to provide a prediction market for biotech, according to STAT’s Elaine Chen.
Merck received FDA approval for its oral PCSK9 inhibitor, expanding cholesterol options.
Researchers reported an understanding of the link between Epstein-Barr virus infection and multiple sclerosis.

1 of 1

Story summary

Kalshi announced it will launch biopharma betting markets that let users wager on trial results and FDA approvals, beginning with markets selected with AppliedXL, a firm that predicts trial outcomes, and aims to provide a prediction market for biotech, according to STAT’s Elaine Chen.
Merck received FDA approval for its oral PCSK9 inhibitor, expanding cholesterol options.
Researchers reported an understanding of the link between Epstein-Barr virus infection and multiple sclerosis.